About Calciscon
Calciscon is a company based in Nidau (Switzerland) founded in 2013. Calciscon has raised $3.35 million across 3 funding rounds from investors including Venture Kick and Yellowstone Holding. Calciscon offers products and services including T50 Test and CPP Measurement Panel. Calciscon operates in a competitive market with competitors including SphingoTec, Astute Medical, Proteomics International, Astek Diagnostics and Cutting Edge Medical Devices, among others.
- Headquarter Nidau, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Calciscon Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.35 M (USD)
in 3 rounds
-
Latest Funding Round
$2.71 M (USD), Series A
Apr 14, 2021
-
Investors
Venture Kick
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Calciscon
Calciscon offers a comprehensive portfolio of products and services, including T50 Test and CPP Measurement Panel.
Measures Calciprotein Crystallization for kidney disease prediction.
Provides comprehensive methods for assessing Calciprotein Particles.
Funding Insights of Calciscon
Calciscon has successfully raised a total of $3.35M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.71 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Calciscon
Calciscon has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Venture Kick and Yellowstone Holding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
University backed startup accelerator
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Calciscon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Calciscon
Investment portfolio details for Calciscon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Calciscon
Detailed financials for Calciscon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Calciscon Comparisons
Peer comparison for Calciscon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Calciscon
Calciscon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SphingoTec, Astute Medical, Proteomics International, Astek Diagnostics and Cutting Edge Medical Devices, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed.
|
|
| Locked | Locked | Locked |
Biomarkers are identified for diagnosing high-risk medical conditions.
|
|
| Locked | Locked | Locked |
Medical technology company at the forefront of predictive diagnostics and bio-analytical services
|
|
| Locked | Locked | Locked |
Blood test diagnostic devices are manufactured by Astek Diagnostics.
|
|
| Locked | Locked | Locked |
Developing devices for analyzing proteins, cancer screening, asthama and infant care management
|
Detailed competitors of Calciscon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calciscon
Complete news archive for Calciscon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Calciscon
Calciscon was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Calciscon is headquartered in Nidau, Switzerland. It is registered at Nidau, Bern, Switzerland.
Andreas Pasch is the current CEO of Calciscon.
Calciscon is a funded company, having raised a total of $3.35M across 3 funding rounds to date.
Developer of a blood-based IVD to test propensity for pathological calcification. In parallel, new therapies for the prevention of calcification are planned using the test kit for monitoring and guidance of personalized treatments. The T50-Test measures the maturation time of CalciProtein Particles (CPPs) by nephelometry. The test integrates the interplay of calcification inhibiting and promoting forces inherent in the blood into a single readout. The key target market is patients with chronic kidney disease stage 35 and those that are to undergo dialysis, and kidney transplantation. The T50-Test has already been shown to be highly predictive of patient survival, transplant graft failure, and the progression of aortic stiffness in kidney patients.
Calciscon's top competitors include SphingoTec, Proteomics International and Astute Medical.
Calciscon offers T50 Test and CPP Measurement Panel.
Calciscon has 2 investors. Key investors include Venture Kick, and Yellowstone Holding.